Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Long-Term Investments: 2024-2025

Historic Long-Term Investments for Dianthus Therapeutics (DNTH) over the last 1 years, with Sep 2025 value amounting to $152.9 million.

  • Dianthus Therapeutics' Long-Term Investments rose 148.65% to $152.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.9 million, marking a year-over-year increase of 148.65%. This contributed to the annual value of $81.7 million for FY2024, which is N/A change from last year.
  • Per Dianthus Therapeutics' latest filing, its Long-Term Investments stood at $152.9 million for Q3 2025, which was up 195.67% from $51.7 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Long-Term Investments registered a high of $152.9 million during Q3 2025, and its lowest value of $51.7 million during Q2 2025.
  • In the last 2 years, Dianthus Therapeutics' Long-Term Investments had a median value of $68.3 million in 2025 and averaged $83.2 million.
  • Data for Dianthus Therapeutics' Long-Term Investments shows a peak YoY surged of 148.65% (in 2025) over the last 5 years.
  • Dianthus Therapeutics' Long-Term Investments (Quarterly) stood at $81.7 million in 2024, then surged by 148.65% to $152.9 million in 2025.
  • Its last three reported values are $152.9 million in Q3 2025, $51.7 million for Q2 2025, and $68.3 million during Q1 2025.